Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis
- 1 May 2017
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 77, 48-56
- https://doi.org/10.1016/j.ejca.2017.02.028
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceLeukemia & Lymphoma, 2013
- Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparisonSupportive Care in Cancer, 2012
- Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular responseBlood, 2012
- Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trialsHaematologica, 2012
- Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemiaCytokine, 2012
- Discontinuation of imatinib in Japanese patients with chronic myeloid leukemiaHaematologica, 2011
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With ImatinibJNCI Journal of the National Cancer Institute, 2011
- Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferonBritish Journal of Haematology, 2000